160 related articles for article (PubMed ID: 16923108)
21. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.
Antonioli E; Guglielmelli P; Pancrazzi A; Bogani C; Verrucci M; Ponziani V; Longo G; Bosi A; Vannucchi AM
Leukemia; 2005 Oct; 19(10):1847-9. PubMed ID: 16079890
[No Abstract] [Full Text] [Related]
23. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
Tefferi A; Lasho TL; Schwager SM; Strand JS; Elliott M; Mesa R; Li CY; Wadleigh M; Lee SJ; Gilliland DG
Cancer; 2006 Feb; 106(3):631-5. PubMed ID: 16369984
[TBL] [Abstract][Full Text] [Related]
24. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia.
Puigdecanet E; Espinet B; Lozano JJ; Sumoy L; Bellosillo B; Arenillas L; Alvarez-Larrán A; Solé F; Serrano S; Besses C; Florensa L
Leukemia; 2008 Jul; 22(7):1368-76. PubMed ID: 18480837
[TBL] [Abstract][Full Text] [Related]
26. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients.
Pardanani A; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Hanson CA; Tefferi A
Leukemia; 2010 Jan; 24(1):110-4. PubMed ID: 19847198
[TBL] [Abstract][Full Text] [Related]
27. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.
Panova-Noeva M; Marchetti M; Spronk HM; Russo L; Diani E; Finazzi G; Salmoiraghi S; Rambaldi A; Barbui T; Ten Cate H; Falanga A
Am J Hematol; 2011 Apr; 86(4):337-42. PubMed ID: 21442635
[TBL] [Abstract][Full Text] [Related]
28. [Correlations of jak2v617f mutation with clinical and laboratory findings in primary thrombocythemia patients].
Xia J; Xu W; Zhang SJ; Sun XM; Duan LM; Li WD; Qiou HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):416-20. PubMed ID: 18426677
[TBL] [Abstract][Full Text] [Related]
29. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
Patel RK; Lea NC; Heneghan MA; Westwood NB; Milojkovic D; Thanigaikumar M; Yallop D; Arya R; Pagliuca A; Gäken J; Wendon J; Heaton ND; Mufti GJ
Gastroenterology; 2006 Jun; 130(7):2031-8. PubMed ID: 16762626
[TBL] [Abstract][Full Text] [Related]
31. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
32. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
33. [Quantitative analysis for JAK2 mutation in 98 patients with essential thrombocythemia and its clinical significance].
Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):665-9. PubMed ID: 19549384
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
[TBL] [Abstract][Full Text] [Related]
35. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
36. Mutation screening for JAK2V617F: when to order the test and how to interpret the results.
Tefferi A; Pardanani A
Leuk Res; 2006 Jun; 30(6):739-44. PubMed ID: 16460800
[TBL] [Abstract][Full Text] [Related]
37. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.
Petrides PE; Siegel F
Blood Cells Mol Dis; 2006; 36(3):379-84. PubMed ID: 16563815
[TBL] [Abstract][Full Text] [Related]
38. Dysfunction of the PI3 kinase/Rap1/integrin α(IIb)β(3) pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia.
Moore SF; Hunter RW; Harper MT; Savage JS; Siddiq S; Westbury SK; Poole AW; Mumford AD; Hers I
Blood; 2013 Feb; 121(7):1209-19. PubMed ID: 23243278
[TBL] [Abstract][Full Text] [Related]
39. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia.
Stauffer Larsen T; Hasselbalch HC; Pallisgaard N; Møller MB
APMIS; 2007 Nov; 115(11):1267-73. PubMed ID: 18092959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]